Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT06574360

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Led by China Medical University Hospital · Updated on 2026-03-24

90

Participants Needed

1

Research Sites

231 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

sigma-1 receptor (S1R) agonistic property have been tested in clinical trials for the treatment of schizophrenia. In addition, previous studies found that some NMDA receptor (NMDAR)-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. Whether combined treatment of an S1R agonist and an NMDA-enhancing agent can be better than an S1R agonist alone deserves study.

CONDITIONS

Official Title

Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a DSM-5 diagnosis of schizophrenia
  • Resistant to adequate treatments with at least two antipsychotics (excluding clozapine)
  • Remain symptomatic without significant fluctuations, with unchanged antipsychotic doses for at least 3 months
  • PANSS total score greater than 70
  • Hamilton Depression Rating Scale-17 items (HAMD) score less than 7
  • Physically healthy with clinically insignificant laboratory assessments
  • Have sufficient education to communicate and complete study assessments
  • Agree to participate and provide informed consent
Not Eligible

You will not qualify if you...

  • Diagnosis of intellectual disability or substance use disorder (including alcohol) according to DSM-5
  • History of epilepsy, head trauma, central nervous system diseases, or mental disorders other than schizophrenia
  • Pregnancy or lactation
  • Inability to follow the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here